Therapeutic resistance remains one of oncology’s most difficult challenges. Cancer cells are genetically and biologically adaptable, and treatment can select for populations that activate alternative pathways to repair damage, continue dividing or evade cell death. As a result, a therapy that produces a strong response at first may eventually lose its effect, allowing the disease to return. “Therapeutic resistance is a main obstacle to achieve effective and durable cancer treatments,” said Dr. Weei-Chin Lin, professor of medicine—hematology and oncology and of molecular and cellular biology at Baylor, who led the study.

The Baylor team focused on TopBP1 because the protein functions as a kind of molecular switchboard. Rather than controlling only one process, TopBP1 coordinates multiple pathways involved in DNA replication, DNA damage responses and cancer-cell survival. The researchers concentrated on a region known as the BRCT7/8 domain, which acts as a docking interface for other regulatory proteins. Interrupting this interface could therefore affect several cancer-promoting systems at once, potentially reducing the ability of malignant cells to compensate when one pathway is blocked.

Among the proteins that interact with TopBP1-BRCT7/8 are MIZ1, a regulator that can suppress the cancer-driving protein MYC; mutant forms of p53, which may acquire functions that actively promote tumor growth; and PLK1 and CIP2A, proteins that support cell division and help cancer cells withstand stress. These interactions give TopBP1-BRCT7/8 an unusually broad influence over tumor biology. The researchers reasoned that a compound capable of selectively disrupting the domain might weaken several lines of defense at the same time.

To find such a compound, the team combined computer-based structural modeling with laboratory screening. Thousands of chemical molecules were evaluated for their ability to fit into the BRCT7/8 binding region and interfere with its interactions. An initial hit, called 3B6, provided a chemical starting point, but it was not sufficiently effective to serve as a promising drug candidate. Researchers chemically modified the compound through multiple rounds of optimization, ultimately producing CS18, which displayed stronger activity in cellular experiments.

The experiments indicated that CS18 affects cancer cells through several connected mechanisms. When the compound binds to TopBP1-BRCT7/8, the activity of MYC and mutant p53 declines, while proteins involved in DNA repair become less effective. At the same time, genes that restrict uncontrolled cell growth become more active. This combination may leave cancer cells unable to repair treatment-induced damage or maintain the signaling programs required for survival, increasing the likelihood that they will undergo programmed cell death.

CS18 produced these effects across a range of malignant cell types, including triple-negative breast cancer, ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma and acute myeloid leukemia. In the researchers’ tests, the compound was less damaging to noncancerous cells than to cancer cells, although such findings do not establish safety in humans. The broad activity was particularly important because it suggested that TopBP1 inhibition could be relevant across tumors driven by different genetic abnormalities rather than being limited to a single cancer subtype.

The most notable results emerged when CS18 was combined with existing treatments. In cancer models, the compound enhanced the activity of PARP inhibitors, drugs that prevent cells from repairing certain forms of DNA damage. Tumor cells already operating under heavy replication and repair stress may be especially dependent on the remaining repair pathways, making them vulnerable when TopBP1 signaling is also disrupted. CS18 likewise strengthened the effect of osimertinib, a targeted therapy used against certain lung cancers driven by mutant epidermal growth factor receptor, or EGFR.

The combination was particularly effective in cells that had already developed resistance to osimertinib. Adding CS18 restored their sensitivity to the EGFR inhibitor and increased cancer-cell death, indicating that TopBP1 blockade may help dismantle resistance mechanisms rather than simply adding another independent source of toxicity. In animal models, treatment combinations significantly reduced tumor growth without major weight loss or other obvious signs of toxicity during the experiments. However, the results remain preclinical, and further studies will be needed to determine how the compound is absorbed, distributed and metabolized, as well as whether its benefits outweigh potential risks in people.

The researchers describe CS18 as a candidate for further drug development, not as an available cancer treatment. Additional work will need to establish the compound’s precise pharmacology, optimal dosing, long-term safety and effectiveness in more representative tumor models. Clinical trials would ultimately be required to determine whether the strategy can help patients whose cancers resist PARP inhibitors, osimertinib or other therapies. If those studies are successful, targeting TopBP1-BRCT7/8 could lead to combination treatments designed not only to shrink tumors, but also to prevent cancer cells from activating escape routes that enable relapse.

Subject of Research: Cells

Article Title: Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance

Web References: https://doi.org/10.1126/sciadv.aeg1996; https://www.bcm.edu/people-search/weei-chin-lin-25464

References: Science Advances, DOI: 10.1126/sciadv.aeg1996

Keywords

CS18, TopBP1, cancer drug resistance, cancer therapy, PARP inhibitors, osimertinib, lung cancer, triple-negative breast cancer, ovarian cancer, acute myeloid leukemia, molecular oncology, drug development

BTK inhibitors work by suppressing Bruton’s tyrosine kinase, an enzyme that transmits signals essential for the growth, survival and activation of B cells. Because mantle cell lymphoma and several other B-cell malignancies depend heavily on these signaling pathways, drugs that inhibit BTK can produce powerful clinical responses. Yet the benefit is often temporary. Many patients relapse after one or two years as lymphoma cells acquire or select for biological changes that allow them to survive despite continued treatment.

The new study, published in Nature Communications, identifies an unexpected mechanism behind this resistance. In mantle cell lymphoma cells that remain sensitive to BTK inhibitors, treatment triggers ferroptosis rather than simply starving the cells of growth signals. Ferroptosis is a distinct form of regulated cell death driven by the uncontrolled oxidation of lipids, the fatty molecules that form cellular membranes. As oxidized lipids accumulate, the membrane loses its integrity and eventually ruptures, killing the cell.

This process depends on the presence of both reactive oxygen species and available iron. Iron can catalyze chemical reactions that convert relatively stable oxygen-containing molecules into highly reactive compounds. These reactions initiate a chain reaction in membrane lipids, producing toxic lipid peroxides. Healthy cells normally prevent this damage through antioxidant systems, but rapidly dividing cancer cells operate under substantial metabolic stress and can become especially vulnerable when those defenses are disrupted.

Dr. Soo-Yeon Hwang, a postdoctoral associate in the laboratory of Dr. Jihye Paik at Weill Cornell Medicine, and colleagues compared lymphoma cells obtained from patients who responded to BTK inhibitors with cells from patients whose cancers had become resistant. The distinction was striking. BTK treatment induced the molecular and biochemical features of ferroptosis in sensitive cells, while resistant cells avoided the same fate. The researchers traced this difference to abnormal activity of BRG1, a protein that regulates how DNA is packaged and read.

BRG1 is a chromatin remodeler, meaning that it helps rearrange the structure of chromatin—the complex of DNA and proteins inside the nucleus. By repositioning nucleosomes, the compact units around which DNA is wrapped, chromatin remodelers can make particular genes more or less accessible to the transcriptional machinery. This gives them broad influence over cellular behavior. In mantle cell lymphoma, BRG1 is frequently mutated or otherwise dysregulated in tumors that no longer respond to BTK inhibitors.

The researchers found that aberrant BRG1 rewires gene expression in a way that suppresses ferroptosis. Its activity reduces the cellular conditions required for the death process, including the accumulation of reactive oxygen and free iron. In effect, BRG1 acts as a protective shield: while BTK inhibition places the lymphoma cell under stress, BRG1 strengthens the cell’s ability to neutralize oxidative damage before it can spread through the membrane.

This finding helps explain why simply continuing BTK inhibitor treatment may fail even when the drug remains capable of blocking its original molecular target. Resistance does not necessarily arise because the lymphoma cell restores BTK signaling. Instead, the cell can bypass the lethal consequences of BTK inhibition by changing its metabolism and antioxidant defenses. BRG1 therefore represents a vulnerability downstream of the drug’s primary target, one that may be exploitable even after the cancer has stopped responding to BTK therapy.

In laboratory experiments and animal models, combining a BRG1 inhibitor with a BTK inhibitor substantially increased antitumor activity compared with BTK inhibition alone. The combination also extended survival in treated animals. These results provide early evidence for a therapeutic strategy in which the cancer’s antioxidant protection is dismantled while BTK signaling is simultaneously suppressed. The approach could potentially be relevant beyond mantle cell lymphoma, although its safety and effectiveness in people will require clinical testing.

The study also highlights the growing importance of ferroptosis in cancer biology. Unlike apoptosis, the best-known form of programmed cell death, ferroptosis is governed by iron handling, lipid metabolism and cellular redox balance. Because malignant cells frequently divide rapidly and remodel their membranes at high rates, they may carry a biochemical weakness that can be exposed by targeted therapies. The Weill Cornell findings suggest that understanding which tumors retain or suppress this weakness could help guide treatment decisions and reveal combination therapies for patients whose cancers have become resistant.

Web References: https://www.nature.com/articles/s41467-026-75123-4

References: Nature Communications study published 2 July 2026; Weill Cornell Medicine investigators Dr. Soo-Yeon Hwang, Dr. Jihye Paik and Dr. Hongwu Zheng.

Keywords: Mantle cell lymphoma, BTK inhibitors, Bruton’s tyrosine kinase, BRG1, ferroptosis, oxidative stress, cancer drug resistance, B lymphocytes, chromatin remodeling, targeted therapy

Cancer drug resistance arises when a subpopulation of tumor cells acquires or possesses intrinsic mechanisms that allow them to survive despite the administration of potent chemotherapeutic agents or targeted therapies. Historically, unraveling the precise dynamics of how these resistant phenotypes emerge and evolve during treatment has been hindered by technological limitations. Conventional methods often fail to capture the temporal and spatial complexity of tumor heterogeneity, leaving scientists with an incomplete picture of resistance evolution. The study led by Whiting, Mossner, Gabbutt, and their colleagues addresses this gap through an innovative methodology that integrates genetic barcoding with quantitative phenotypic analysis.

Genetic barcoding involves tagging individual cancer cells with unique DNA sequences, effectively labeling each cell as it undergoes proliferation and evolution. By sequencing these barcodes over time, researchers can track the lineage and abundance of distinct cellular clones within a tumor population. This precise lineage tracing enables the detection of subtle shifts in subclonal composition as selective pressures, such as drug treatments, reshape the tumor landscape. The study capitalizes on this to illuminate how phenotype dynamics unfold in a living cancer ecosystem subjected to evolving drug stress.

One striking revelation from this work is the observation that cancer cell populations do not invariably evolve resistance through the expansion of pre-existing resistant clones alone. Instead, there is a dynamic interplay among diverse phenotypes, with some lineages adapting through gradual phenotypic plasticity, while others harness genetic mutations that confer robust drug tolerance. The ability to quantify these dynamics at an unprecedented resolution offers a detailed timeline of resistance evolution, illustrating the heterogeneity and plasticity underlying tumor adaptation.

The research team employed a sophisticated experimental model system, wherein human cancer cell lines were genetically barcoded and then exposed to clinically relevant dosages of chemotherapeutic drugs. Over multiple treatment cycles, the composition and behavior of hundreds of thousands of individual clones were monitored using high-throughput sequencing and single-cell phenotypic profiling. Computational algorithms integrated these data to reconstruct lineage trajectories and phenotypic distributions, creating a temporal map of resistance emergence.

One of the most compelling technical achievements is their development of a computational framework capable of disentangling the intertwined effects of genetic and non-genetic factors on phenotype dynamics. Traditional genetic analyses often overlook the role of epigenetics, transcriptional states, and microenvironmental cues. By incorporating single-cell phenotyping alongside lineage tracing, the researchers demonstrate how transient, non-heritable phenotypic states contribute substantially to the early phases of drug resistance, potentially setting the stage for stable genomic alterations.

Furthermore, the quantitative approach allowed the researchers to deconvolute complex drug response behaviors, revealing that the timing and sequence of phenotypic changes are critical determinants in whether resistance stabilizes or dissipates. Certain subclones exhibited reversible drug-tolerant states that could transiently survive treatment, whereas others accumulated mutations solidifying resistance. This nuanced understanding underscores the importance of therapeutic scheduling and dosing strategies to outmaneuver cancer’s adaptive capacities.

From a translational perspective, this research lays the groundwork for real-time monitoring of tumor evolution in patients. The genetic barcoding technology, although currently applied in preclinical models, promises to be adapted for in vivo applications, potentially via circulating tumor DNA sequencing or tumor biopsies. By profiling the evolving phenotypic landscape of a patient’s tumor during therapy, clinicians might soon predict emergent resistance pathways and personalize treatment regimens accordingly to forestall relapse.

The implications of these findings extend beyond cancer drug resistance. The framework introduced here paves the way for studying phenotypic evolution in other areas of medicine, such as infectious diseases where pathogens develop antibiotic resistance, or in regenerative medicine where tissue stem cells evolve phenotypic heterogeneity. The integration of lineage tracing with functional phenotype measurement represents a new frontier in biology, merging genetics, biophysics, and computational science.

Moreover, this study challenges prevailing dogmas that have dominated cancer biology for decades. By illustrating that drug resistance is not merely a product of fixed genetic mutations but a continuum involving dynamic phenotypic plasticity, it calls for a paradigm shift in both research priorities and therapeutic development. Drugs designed solely to target genetic mutations might fall short unless they also address the underlying reversible phenotypic states that enable initial survival.

Intricately detailed in the experimental design is the use of advanced single-cell technologies, including fluorescence-activated cell sorting (FACS) and high-resolution microscopy, to phenotype cells alongside barcode sequencing. This multimodal analysis revealed subtle morphological and metabolic traits correlated with resistance states, providing biomarkers that could be exploited for diagnostic or therapeutic interventions. The ability to link phenotype and genotype at single-cell resolution is a pivotal advancement made possible by this work.

The scientific community will undoubtedly be watching with keen interest how these findings influence ongoing clinical trials and the development of next-generation cancer treatments. While genetic barcoding has primarily been a research tool, its emerging clinical relevancy is exciting. Future iterations may include integrating it with immunotherapy research, where phenotypic adaptation of tumor cells to immune pressures similarly challenges treatment durability.

In summary, Whiting and colleagues have delivered a seminal contribution to cancer biology with their meticulous quantitative analysis of phenotype dynamics during the evolution of drug resistance. By harnessing the power of genetic barcoding and sophisticated phenotypic measurements, they expose the layered complexity of tumor adaptation, offering hope for new diagnostic and therapeutic strategies capable of outpacing cancer’s rapid evolution. This landmark study marks a decisive step forward in the endeavor to transform cancer from a deadly adversary into a manageable chronic condition.

The road ahead will require integrating these insights with clinical workflows and expanding the technology to heterogeneous patient populations and diverse cancer types. Nevertheless, the framework established in this research sets an inspiring precedent—one where the intricate dance of cellular evolution can be observed, understood, and ultimately controlled. As the fight against cancer continues, such innovative approaches herald a new era of precision oncology grounded in deep mechanistic understanding.

Subject of Research: Dynamics of cancer drug resistance evolution studied through genetic barcoding and quantitative phenotypic analysis.

Article Title: Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding.

Article References:
Whiting, F.J.H., Mossner, M., Gabbutt, C. et al. Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding. Nat Commun 16, 5282 (2025). https://doi.org/10.1038/s41467-025-59479-7

Image Credits: AI Generated